DAVID Y. IGE GOVERNOR



OFFICE OF ENTERPRISE TECHNOLOGY SERVICES P.O. BOX 119, HONOLULU, HAWAI'I 96810-0119 Ph: (808) 586-6000 | Fax: (808) 586-1922 ETS:HAWAII.GOV

July 21, 2020

The Honorable Ronald D. Kouchi, President, and Members of The Senate Twenty-Ninth State Legislature Hawaii State Capitol, Room 409 Honolulu, Hawaii 96813 The Honorable Scott K. Saiki, Speaker, and Members of The House of Representatives Twenty-Ninth State Legislature Hawaii State Capitol, Room 431 Honolulu, Hawaii 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

Pursuant to HRS section 27-43.6, which requires the Chief Information Officer to submit applicable independent verification and validation (IV&V) reports to the Legislature within ten days of receiving the report, please find attached the report the Office of Enterprise Technology Services received for the State of Hawaii Department of Health Hawaii BHA Integrated Case Management System Project.

In accordance with HRS section 93-16, this report may be viewed electronically at <u>http://ets.hawaii.gov</u> (see "Reports").

Sincerely,

DOUGLAS MURDOCK Chief Information Officer State of Hawai'i

Attachment (2)



Hawaii BHA Integrated Case Management System Project – Phase 3

Final IV&V Report for the period of

June 1 – June 30, 2020

Final submitted: July 10, 2020



Solutions that Matter

Agenda

Executive Summary IV&V Findings & Recommendations

Appendices

- A Rating Scales
- B Inputs
- C Project Trends





The project deployed Release 3.9 into production in June and similar to R3.8, ISP Cloning functionality issues were encountered due to deployment issues. Corrective actions have been identified to address the deployment issues which the Project will implement with assistance from RSM.

The RSM Team continued to provide essential support during June alleviating some of the bandwidth concerns expressed by DOH to meet crucial business needs.

The project remains substantially on track with scheduled project tasks/activities and milestones despite the current COVID-19 pandemic.

Apr	Мау	Jun	Category	IV&V Observations
G	G	G	Sprint Planning	The sprint planning category remains Green (low) for the June reporting period, maintaining one active finding for this category. The RSM Team continued to assist the DOH Team with tasks and activities during June and will continue to do so for upcoming releases which helps to alleviate some of the bandwidth concerns for the DOH staff.
G	G	G	User Story (US) Validation	IV&V reports no active findings for User Story (US) Validation category which remains Green (low) for the June reporting period. IV&V will continue to monitor the US development and validation process in upcoming reporting periods.
Y	G	G	Test Practice Validation	IV&V reduced the Test Practice Validation category to Green (low) for the June reporting period as a result of the execution of regression testing for both DDD and CAMHD for Release 3.9. The Project plans on setting up automated regression testing during R3.10 and IV&V will continue to monitor.



Apr	Мау	Jun	Category	IV&V Observations	
Y	Y	Release / The Project has identified corrective actions for preventing a recurrence of future deployment issues and will enlist the assistance of RSM to implement these corrective		deployment issues and will enlist the assistance of RSM to implement these corrective actions. The rating for this category remains as yellow for June and IV&V will continue to	
G	G	G	OJT and KT Sessions	The rating for the OJT and KT Sessions category remains Green (low) for the June reporting period with no active findings.	
G	G	G	Targeted KT	IV&V continues to rate the Targeted KT category at Green (low) for the June reporting period and maintains one active concern in this category. RSM conducted another Calculator 3.0 Knowledge Transfer session on 6/26/2020 and scheduled a final session for 7/17/2020.	
G	G	Image: Generative stateProject Performance MetricsIV&V continues to rate the Project Performance Metrics category Green (low) for the June reporting period. The project met its planned velocity expectation for the R3.9 J 			



Apr	Мау	Jun	Category	IV&V Observations
G	G	G	Organizational Maturity Assessment	IV&V continues to rate the Organization Maturity Assessment (OMA) at Green (low) for the June reporting period. The next OMA will be planned for the next agile release or after R3.11.
Y	Y	Y	Project Management	IV&V closed the backlog grooming finding and reduced the COVID-19 risk from a High to a Medium risk for this category which we will keep a Yellow (medium) for the June reporting period and will revisit in July.



As of the June 2020 reporting period, there are a total of five open findings - two Medium Risks, two Low Risks, one Low Issue along with one Preliminary Concern spread across the Sprint Planning, Release / Deployment Planning, Test Practice Validation, Targeted Knowledge Transfer, and Project Management assessment areas.





IV&V Findings & Recommendations

IV&V Findings & Recommendations Assessment Categories

Throughout this project, IV&V will verify and validate activities performed in the following process areas:

- Sprint Planning
- User Story Validation
- Test Practice Validation
- Release / Deployment Planning
- On-the-Job Training (OJT) and Knowledge Transfer (KT) Sessions
- Targeted Knowledge Transfer (KT)
- Project Performance Metrics
- Organizational Maturity Assessment
- Project Management

IV&V Findings & Recommendations Sprint Planning

#	Key Findings	Criticality Rating
8	Low Risk – The BHA Technical Team bandwidth may not be adequate to meet the needs of the project, which could compromise project productivity. No change during this reporting period. Release 3.10 is being managed by RSM as a water-scrum-fall release, which is helping to limit the impact of minimal bandwidth for the DOH Solution Architect. IV&V will continue to monitor this risk in July.	l

Recommendations	Status
 The Project should investigate mechanisms of increasing the bandwidth of the BHA Technical Team, either by adding resources through new hires, or existing vendor contracts. 	In progress
 The Project should assess, where possible, if there are responsibilities of the BHA Technical Team that can be reassigned to other project staff. 	In progress
 The Project should evaluate where process inefficiencies can be addressed and streamlined to possibly free up the BHA Technical Team's availability. 	In progress



IV&V Findings & Recommendations Test Practice Validation

#	Key Findings	Criticality Rating
2	Low Issue – As a result of regression testing not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production environment. No changes were noted during the June reporting period. The Project Team used its' DDD and CAMHD regression script assets for Release 3.9 in June. The automation of regression testing is still outstanding and is planned to be developed during Release 3.10 and executed for Release 3.11. IV&V will continue to monitor progress.	C

Recommendations	Status
Updating the regression test scripts to ensure consistency with system configuration.	Completed
Modifying release schedules to allow for regression testing timeframes.	Completed
 Planning releases by functionality type to avoid unnecessary repetitive work being performed in any given section of the solution. 	Completed
 Performing regression testing after every release, or possibly every other release, or potentially tying regression tests to full solution upgrade releases. In addition, consider alternating the DDD and CAMHD scripts every other release. 	Completed

IV&V Findings & Recommendations Test Practice Validation (cont'd)

Recommendations	Status
Modifying regression test scripts to start AFTER case creation, limiting the time it takes to execute.	Completed
Modify the deployment scripts based on information gained from previous release deployments.	Completed
 Pursuing additional formal training in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. 	Open
 Consulting with RSM to determine how the 'interim testing processes' can be improved until such time that automated testing is available for repeatable and complete industry standard regression testing. 	Completed
 Implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. 	Completed



IV&V Findings & Recommendations Release / Deployment Planning

#	Key Findings	Criticality Rating
5	Escalated Risk from Low to Medium - Due to the project not following a detailed deployment script, the project may continue to experience defects related to deployment activities. Release 3.9 was promoted to production during the June reporting period. Similar to the mid-sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative and dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/17/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July.	M

Recommendations		Status
•	IVV recommends documenting deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable.	Completed
•	Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions.	Completed



IV&V Findings & Recommendations Release / Deployment Planning (cont'd)

Recommendations	Status
As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	In Progress
 Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. 	Completed
Allow for complete functionality testing in pre-production environments before deploying code to production.	In Progress
 Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. 	New
 Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. 	New
 Ensure an operational and fully functional test environment is available to effectively conduct end-to-end regression testing prior to deploying a release to production. 	New



IV&V Findings & Recommendations Targeted KT

#	Key Findings	Criticality Rating
3	Low Risk – Usage of open source JavaScript framework for development and ongoing maintenance of Calculator 3.0 requires BHA to take a proactive approach to support and security. RSM conducted another Calculator 3.0 Knowledge Transfer session on 6/26/2020 and scheduled a final session for 7/17/2020.	•

Recommendation	S	Status
	ds BHA work to establish a reliable and repeatable process for keeping abreast of tes and support opportunities for a new suite of tools.	Open
suite of tools, ar	ds BHA continue to hold targeted KT sessions with RSM on maintaining Calculator 3.0 via a d determine what additional skillsets, training, and/or resources are needed to support ownership of Calculator 3.0.	In Progress

IV&V Findings & Recommendations Project Management

#	Key Findings	Criticality Rating
7	Closed Low Risk - The lack of consistent backlog grooming could result in the project backlog having obsolete, non-estimated, and poorly defined user stories. IV&V has observed for another month that the project continues to groom the backlog. As a result, we are closing this finding.	Closed

Recommendations	Status
 CAMHD and DDD should prioritize grooming the backlog to bring it as current and accurate as possible. This should include removing items no longer needed, and ensuring all items are fully defined, readying them for configuration or developer resources. To the extent feasible, BHA should involve RSM SMEs in this process, if only for the interim to get "caught up" on grooming efforts. 	Completed
 IVV recommends that the project consider utilizing an age-based methodology for the deprecation of 'older' user stories in the backlog that may no longer be applicable or needed by the Product Owners and developing a process for periodic cleansing of the backlog using the same methodology. 	Completed



IV&V Findings & Recommendations Project Management (cont'd)

#	Key Findings	Criticality Rating
10	Reduced Risk from High to Medium - The COVID-19 pandemic and the related "stay at home" order could hinder project activities and negatively impact the project schedule and budget. The State's 'Safer at Home' orders ended on June 30 th . IV&V notes that although staff are still remote, the project has continued to manage meeting monthly release schedules. As such, IV&V is reducing this risk to a Medium priority.	M

Recommendations		Status
	A to ramp up efforts to setup, train, and assist stakeholders on remote work devices very effort to help them to become highly functional with remote access technology (e.g.	Completed
	e project and DOH create a detailed, documented risk mitigation strategy and plan that and revised to address the current state of the COVID-19 threat and related impacts nonths.	In Progress
	dates to the OCM Plan to include any new activities or updates to planned activities to prough this COVID-19 situation in the short and long term.	Open



IV&V Findings & Recommendations Project Management (cont'd)

#	Key Findings	Criticality Rating
11	Preliminary Concern - The lack of design reviews for complex user stories has resulted in the promotion of incomplete solutions into production. IV&V acknowledges the Project Team continued to spend additional time on the designs of complex user stories during June to ensure requirements and user story components were fully captured in designs. IV&V will continue to monitor in July.	N/A

Recommendations	
 IV&V recommends (and DOH has commenced) conducting technical design reviews for complex user stories prior to development to ensure designs are complete and all requirements associated with the design are met. IV&V observed this activity has been implemented by DOH in the month of June. 	In Progress



IV&V Findings & Recommendations Project Performance Metrics

Metric	Description	IV&V Observations	IV&V Updates
Velocity	 Review and validate the velocity data as reported by the project Verify the project is on pace to hit the total target number of US/USP for Phase 3 	June - During Sprint Planning for Release 3.9, available velocity was calculated as 88 US Points (USP) with a total of 87 USP being released to production.	 June – The project continues to estimate the User Stories in the Backlog. BHA resources are working in sequential order to estimate stories targeting those items tagged with Release 3.10 Iterations 1, 2, and 3.

IV&V Findings & Recommendations Project Performance Metrics (cont'd.)

Metric	Description	IV&V Observations	IV&V Updates
US Point Estimates vs Actuals	 Verify the project is tracking US Point estimates and actual data Determine the delta between estimates and actuals Based on the delta (if any) investigate the potential root cause for the delta 	June - The Project Scrum Master closely tracks the USP on a daily basis. Determining the delta between USP estimates and actuals is work in progress.	June – No change from last month - DDD and CAMHD have standardized a format for resources to track hours. The recording of resource hours is not completed by all team members making it difficult to calculate the variance between actual vs. projected hours.

IV&V Findings & Recommendations Project Performance Metrics (cont'd.)

Metric	Description	IV&V Observations	IV&V Updates
Defect Metrics	 Understand and track the following: Defects by category (bug fixes) US Points assigned to defects in a release vs US Points assigned to planned US in a release 	 June – Release 3.9 was planned for 88 user story points, and 87 user story points were promoted to production on 6/14/2020. 80 User Story Points (92% of the total) were associated with planned user stories 7 User Story Points (8% of the total) were associated with defects from the backlog. IV&V notes that some of the "planned" items were production defects identified through previous releases and prioritized as part of the 3.9 backlog along with requests that resulted in User Stories. 	June – In addition to the R3.10 efforts, the project is working towards a mid- sprint deployment for approximately six (6) M&O items, the majority of which surround ISP Cloning and Calculator 3.0 functionality. It is anticipated that the mid-sprint deployment will be released to production on 7/17/2020.

IV&V Findings & Recommendations Organizational Maturity Assessment

Measure	IV&V Observations
The Organizational Maturity A	ssessment (OMA) is updated on a bi-monthly basis. The next OMA will be planned for the next agile

release which is after the R3.10 & R3.11 scrum-waterfall releases.



Appendix A: IV&V Rating Scales

Appendix A IV&V Rating Scales

This appendix provides the details of each finding and recommendation identified by IV&V. Project stakeholders are encouraged to review the findings and recommendations log details as needed.

- See Findings and Recommendations Log (provided under separate cover)
- IV&V Assessment Category Rating Definitions

The assessment category is under control and the current scope can be delivered within the current schedule.

The assessment category's risks and issues have been identified, and mitigation activities are effective. The overall impact of risk and issues is minimal.

The assessment category is proceeding according to plan (< 30 days late).

The assessment category is under control but also actively addressing resource, schedule or scope challenges that have arisen. There is a clear plan to get back on track.

The assessment category's risk and/or issues have been identified, and further mitigation is required to facilitate forward progress. The known impact of potential risks and known issues are likely to jeopardize the assessment category.

Schedule issues are emerging (> 30 days but < 60 days late).

Project Leadership attention is required to ensure the assessment category is under control.

The assessment category is not under control as there are serious problems with resources, schedule, or scope. A plan to get back on track is needed.

The assessment category's risks and issues pose significant challenges and require immediate mitigation and/or escalation. The project's ability to complete critical tasks and/or meet the project's objectives is compromised and is preventing the project from progressing forward.

Significant schedule issues exist (> 60 days late). Milestone and task completion dates will need to be re-planned. Executive management and/or project sponsorship attention is required to bring the assessment category under control.



Appendix A Criticality Ratings

Criticality Rating	Definition
8	A high rating is assigned if there is a possibility of substantial impact to product quality, scope, cost, or schedule. A major disruption is likely, and the consequences would be unacceptable. A different approach is required. Mitigation strategies should be evaluated and acted upon immediately.
M	A medium rating is assigned if there is a possibility of moderate impact to product quality, scope, cost, or schedule. Some disruption is likely, and a different approach may be required. Mitigation strategies should be implemented as soon as feasible.
0	A low rating is assigned if there is a possibility of slight impact to product quality, scope, cost, or schedule. Minimal disruption is likely, and some oversight is most likely needed to ensure that the risk remains low. Mitigation strategies should be considered for implementation when possible.



Appendix B: Inputs



Appendix B Inputs

This appendix identifies the artifacts and activities that serve as the basis for the IV&V observations.

Meetings attended during the June 2020 reporting period:

- 1. Daily Scrum Meetings (selected)
- 2. Twice Weekly RSM Issues Meeting
- 3. Release 3.9 Deployment Planning Meeting
- 4. Release 3.8 Retrospective Meeting
- 5. Weekly CCB Meeting
- 6. Weekly BHA-ITS Project Status Meeting
- 7. Bi-Weekly Check-in: CAMHD
- 8. Bi-Weekly Check-in: DDD
- 9. BHA IAPDU Planning Meeting
- 10. DHS Interfaces Meeting
- 11. IV&V Draft IV&V Status Review Meeting with DOH
- 12. IV&V Draft IV&V Status Review Meeting with RSM and DOH
- 13. Calculator 3.0 DOH Knowledge Transfer Session

Eclipse IV&V[®] Base Standards and Checklists



Artifacts reviewed during the June 2020 reporting period:

- 1. Daily Scrum Notes (selected)
- 2. Twice Weekly Issues Meeting Notes (selected)
- 3. Release Notes R3.9
- 4. Phase 3 and Future Phase Extract from TFS Spreadsheet



Appendix C: Project Trends

Appendix C Project Trends

Trend: Overall Project Health											
	20)19				20)20				
Process Area	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Sep	
User Story Validation	N/A										
Test Practice Validation	N/A										
Sprint Planning	N/A										
Release / Deployment Planning	N/A										
OJT and KT Sessions	N/A										
Targeted KT	N/A										
Project Performance Metrics	N/A										
Organizational Maturity Metrics	N/A										
General Project Management	N/A	N/A									
										1	
Total Open Findings	N/A	3	7	5	6	6	6	6			
Issue - high	N/A	0	1	1	0	0	0	0			
Issue - medium	N/A	0	0	0	1	1	0	0			
Issue - low	N/A	0	0	0	0	0	1	1			
Risk - high	N/A	0	0	0	1	1	1	0			
Risk - medium	N/A	0	0	1	1	0	0	2			
Risk - low	N/A	0	1	1	3	4	3	2			
Preliminary Concern	N/A	3	5	2	0	0	1	1			





Solutions that Matter

FINAL IVV Findings Log Jun 2020_V1

ID No	Identified Date	Title	Observation	Significance	Recommendation	Updates	Process Area	Finding Type	Priority	Status	Closure Reason	Risk Owner
1.000		practices.	following topics as they relate to Sprint Planning and the project's overall approach to agile software development: - IV&V acknowledges that the project is now planning three sprints outs, however, it appears that only a "high- level" sprint planning roadmap has been produced, and it is unclear exactly how	is good, the project should be able to identify what feature enhancements will be targeted for each planned release. This roadmap will help the project manage scope and productivity. Relatedly, the "definition done" is an important artifact to ensure that the project is successful.		resourcing, and backlog grooming in new, separate	Sprint Planning	Concern	N/A	Closed	Due to multiple new items being tracked at a more granular level, this item has been closed.	V Ramesh
2.000	12/31/2019	being consistently performed, production releases are both breaking and deprecating existing functionality in the production environment.	R3.3 introduced a defect that deprecated features in production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being deprecated after a release, some of which are still being investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA) process used to determine why such functionality was deprecated but will discuss further with BHA in January 2020.	Thorough vetting and validation of regression test cases is necessary to prevent both defects and the deprecation of production functionality when a release is pushed live. When defects occur in production, the project should follow a defined and repeatable process for determining the root cause of the problem.	To address regression testing, the Project should continue to pursue and/or consider: 1. Updating the regression test scripts to ensure consistency with system configuration. 2. Modifying release schedules to allow for regression testing timeframes 3. Grouping releases by functionality type to avoid unnecessary repetitive work being performed in any given section of the solution. 4. Performing regression testing after every release, or possibly every other release, or potentially tying regression tests to full solutior upgrade releases. In addition, consider alternating the DDD and CAMHD scripts every other release. 5. Modifying regression test scripts to start AFTER case creation, limiting the time it takes to execute. 6. Potentially modifying the deployment scripts based on information gained from any or all of the steps listed above. 7. Pursuing additional formal training in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. 8. Consult with RSM to determine how the finterim testing processes' can be improved until such time that automated testing is available for repeatable and complete industry standard regression testing.	The automation of regression testing is still outstanding and is planned to be developed during Release 3.10 and executed for Release 3.11. IV&V will continue to monitor progress. 05/31/2020 - CAMHD has invested resources to develop end-to-end regression test scripts, which reduces the time necessary to execute this testing on a recurring basis. Both DDD and CAMHD regression scripts were executed for release 3.8. As a result, IV&V is reducing this issue to a low criticality. Automating regression testing is still outstanding and is planned to occur during Release 3.10. IV&V will continue to monitor progress. 04/30/2020 - DDD has invested resources to develop end-to-end regression test scripts, which reduced the time necessary to execute this testing on a recurring basis. DDD successfully performed end-to-end regression testing prior to the production promotion of R3.7.		Issue	Low	Open		D Macdonald

3.000	12/31/2019	Usage of open source JavaScript	IV&V learned in December 2019 that	Open source tools and frameworks	IV&V recommends BHA research and determine	06/30/2020 - The project continued to focus attention	Targeted KT	Risk	Low	Open	D Macdonal
		framework for development and	the Calculator 3.0 functionality is built in	offer organizations great	the long-term sustainability of Vue.JS for	on the Calculator 3.0 defects during the month of June.	-				
		ongoing maintenance of Calculator 3.0	Vue.JS, an open source JavaScript	opportunities to build and	Calculator 3.0 and work to establish a reliable	RSM conducted another Calculator 3.0 Knowledge					
		requires BHA to take a proactive	framework. As this framework is	configure customized solutions at	and repeatable process for keeping abreast of	Transfer session on 6/26/2020 and scheduled a final					
		approach to support and security.	relatively new, the open source support	lower costs than through software	communal updates and support opportunities.	session for 7/17/2020.					
			community is small. IV&V's concerns	purchase or licensing. However,	Additionally, IV&V recommends BHA continue						
			include:	open source tools and frameworks	to hold targeted KT sessions with RSM on	05/31/2020 - The project continued to focus attention					
			- The availability of reliable support for	often do not come with support	maintaining Calculator 3.0 using Vue.JS, and	on the Calculator 3.0 user stories and defects during the					
			Vue.JS	models, other than those offered	determine what additional skillsets, training,	month of May. RSM conducted another Calculator 3.0					
			- The project's understanding of any	through the tool's community.	and/or resources are needed to support BHA's	Knowledge Transfer session on 5/29/2020 which IV&V					
			known vulnerabilities with Vue.JS, and	Because of this, the organization	long-term ownership of Calculator 3.0.	attended. This session included the new C3.0 year-end					
			development of a process to remain	bears the weight of seeking out		changes. Additional KT sessions is planned for and IV&V					
			current on vulnerabilities discovered by	reliable help and support, as well		will continue to monitor this project component during					
			the support community.	as much take a proactive approach		June.					
			- The RSM lead for Calculator 3.0 went	to security and identifying any							
			on extended parental leave in	vulnerabilities in the tools.		04/30/2020 - The project continued to focus its					
			December 2019			attention on Calculator 3.0 User Stories and bug fixes					
			IV&V acknowledges that BHA has			during the month of April. The project scheduled a					
			downloaded Vue.JS to start getting			Calculator 3.0 KT session on April 30, 2020 which IV&V					
			familiar with it.			attended. Additional KT					
						sessions have been discussed and will be scheduled.					
						IV&V will continue to monitor this project component					
						during May.					
						02/21/2020 Again there uses as a hotestice of					
						03/31/2020 - Again there was no substantive change to					
						this finding during the March reporting period, as the					
						project focused its attention for the month to Calculator					
						3.0 User Stories and bug fixes, as opposed to Knowledge Transfer. The project is targeting to potentially schedule					
						the next Knowledge Transfer session on this component during April.					
00	1/31/2020	Due to the project not following a	There have been several defects pushed		IVV recommends documenting deployment	during April. 06/30/2020 - Release 3.9 was promoted to production	Release /	Risk	Med	Open	D Macdona
00	1/31/2020	Due to the project not following a detailed deployment script, the project	There have been several defects pushed to production with Phase 3 releases.	A complete, up to date, and documented deployment script is	IVV recommends documenting deployment scripts for both the patch method and the full	during April.	Deployment	Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects	to production with Phase 3 releases. Some of the defects introduced to	documented deployment script is needed to ensure the repeatability	scripts for both the patch method and the full solution upgrade method. The script(s) should	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning		Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down	documented deployment script is needed to ensure the repeatability and stability of DOH's production	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in	Deployment	Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities.	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments	Deployment	Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical	Deployment	Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components	Deployment	Risk	Med	Open	D Macdona
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments.	Deployment	Risk	Med	Open	D Macdona
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components,	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable.	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a	Deployment	Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED)	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to	Deployment	Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and	Deployment	Risk	Med	Open	D Macdoni
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint	Deployment	Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to	Deployment	Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects.	Deployment	Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low	Deployment	Risk	Med	Open	D Macdon
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment pera, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED)	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects.	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July.	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress)	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre-	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre- production environments before deploying code	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project team is producing effective deployment scripts, which has resulted in repeatable deployment activities.	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre- production. (In Progress)	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project team is producing effective deployment scriipts, which has resulted in repeatable deployment activities. However, in a mid-sprint push to production on	Deployment	Risk	Med	Open	D Macdor
20	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre- production. (In Progress) Request the assistance of the RSM Solution	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project team is producing effective deployment acripts, which has resulted in repeatable deployment scripts, which has resulted in repeatable deployment scripts.	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre- production environments before deploying code to production. (In Progress) Request the assistance of the RSM Solution Architect in reviewing and correcting issues	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project team is producing effective deployment activities. However, in a mid-sprint push to production on 5/22/2020, ISP Cloning features were not successfully deployed to production. The ISP cloning functionality	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre- production (in Progress) Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determing and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project team is producing effective deployment scripts, which has resulted in repeatable deployment activities. However, in a mid-sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production. The ISP cloning functionality was successfully tested in the test environment,	Deployment	Risk	Med	Open	D Macdoi
	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre- production environments before deploying code to production. (In Progress) Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project team is producing effective deployment activities. However, in a mid-sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production. The ISP cloning functionality was successfully tested in the test environment, however the absence of Azure functionality needed in	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre- production (In Progress) Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that test environments can test ALL functions of	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project team is producing effective deployment activities. However, in a mid-sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production. The ISP cloning functionality was successfully tested in the test environment, however the absence of Azure functionality needed in the UAT and SIT2 environments prevented additional	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre- production environments before deploying code to production. (In Progress) Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that test environments can test ALL functions of any given release. (NEW)	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project team is producing effective deployment activities. However, in a mid-sprint push to production on 5/22/2020, ISP Cloning features were not successfully deployed to production. The ISP cloning functionality was successfully tested in the test environment, however the absence of Azure functionality needed in the UAT and SIT2 environments prevented additional final pre-production testing of these features prior to	Deployment	Risk	Med	Open	D Macdor
00	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre- production environments before deploying code to production. (In Progress) Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that test environments can test ALL functions of any given release. (NEW) Request the assistance of the RSM Solution	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to producting diffective deployment scripts, which has resulted in repeatable deployment activities. However, in a mid-sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production. The ISP cloning functionality was successfully tested in the test environment, however the absence of Azure functionality needed in the UAT and SIT2 environments prevented additional final pre-production. IV&V notes BHA has since	Deployment	Risk	Med	Open	D Macdor
0	1/31/2020	detailed deployment script, the project may continue to experience defects related to deployment activities.	to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for	documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when	scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process, and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. (COMPLETED) Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. (COMPLETED) As appropriate, consut with RSM on best practices that BHA could employ to support deployment. (In Progress) Allow for complete functionality testing in pre- production environments before deploying code to production. (In Progress) Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that test environments can test ALL functions of any given release. (NEW)	during April. 06/30/2020 - Release 3.9 was promoted to production during the June reporting period. Similar to the mid- sprint push to production on 5/22/2020, ISP cloning features were not successfully deployed to production in this release. When updating non-prod environments with production data, the project discovered technical issues involving workflow and Azure components creating inconsistencies between test environments. The Project acknowledged that this will take a collaborative, dedicated effort to resolve and plans to enlist the assistance of RSM in determining and implementing corrective actions. A mid-sprint deployment is currently planned for 7/10/2020 to address M&O, ISP Cloning, and Calculator 3.0 defects. IV&V has moved the priority for this finding from Low back to Medium for June and will continue to monitor in July. 05/31/2020 - Release 3.8 was successfully promoted to production during the May reporting period. The project team is producing effective deployment activities. However, in a mid-sprint push to production on 5/22/2020, ISP Cloning features were not successfully deployed to production. The ISP cloning functionality was successfully tested in the test environment, however the absence of Azure functionality needed in the UAT and SIT2 environments prevented additional final pre-production testing of these features prior to	Deployment	Risk	Med	Open	D Macdo

6.000	The project lacks a documented 'Definition of Done", which could challenge the project's ability to fully achieve the goals of Phase 3.	BHA does not have a documented 'Definition of Done' (DOD) for the BHA Top 100 User Stories of for Phase 3. Because of this, it is unclear how proposed functionality/features are prioritized for each sprint, and throughout Phase 3.	guides the Project's vision, business, and technical goals that are important inputs for stakeholders to develop a Roadmap for Phase 3. Without the 'Definition of Done' document, the	Project is currently in the process of creating the Definition of Done. IV&V recommends that the project create this document and socialize this with project team before end of Feb 2020 IV&V recommends that the project consider the items from the prioritized list, available resources and define "Done" as a percentage of the identified priority list with room for flexibility to add any other features/enhancements that will be identified during Phase 3.	Definition of Done and progress against it but is closing	Project Management	Concern	N/A	Closed	Definition of Done completed and socialized.	V Ramesh
7.000	The lack of consistent backlog grooming could result in the project backlog having obsolete, non-estimated, and poorly defined user stories.	The backlog of defects, requests, and user stories continues to grow. Currently, there are approximately 429 defects and requests, of which almost 200 have a status of 'New'. IVV notes that a large percentage of the backlogged work items do not have user story points estimated. Many of the items listed in the backlog are old, and some may have had needs or requirements change over time or may now be obsolete. IV&V notes that DDD and CAMHD have initiated this effort and agreed to prioritize grooming the backlog by the end of February.	A comprehensive, up-to-date backlog is a primary tenet of agile software development. If a backlog is carrying work items that may not ever be completed for any reason, they should be removed from the backlog to ensure its viability.	items that are not yet fully defined, readying them for configuration or developer resources. To the extent feasible, BHA should involve RSM SMEs in this process, if only for the interim to get "caught up" on grooming efforts. (Closed) VV recommends that the project consider utilizing an age-based methodology for the		Project Management	Risk	Low	Closed	The project has demonstrated they are consistently grooming the backlog.	D Macdonald

	1/31/2020	The BHA Technical Team bandwidth may not be sufficient to meet the needs of the project, which could compromise project productivity.		efforts of all technical DOH staff on the project. As such, the Team's time is both extremely valuable and scarce. If the Team's expected workload exceeds bandwidth, the project could experience bottlenecks. Optimization of the BHA Technical Team's time is to the benefit of the project and plays a critical role in the project's ability to hit performance targets and achieve the Phase 3 definition of done.	Solution Architect, either by bringing in additional resources through new hires, or through existing vendor contracts. Additionally, the project should assess, where possible, if there are responsibilities of the Solution Architect that can be reassigned to other project staff. Further, the Project should evaluate where process inefficiencies can be addressed and streamlined to possibly free up the Solution Architect's availability.	Release 3.10 is being managed by RSM as a water-scrum- fall release, which is helping to limit the impact of minimal bandwidth for the DOH Solution Architect. IV&V will continue to monitor this risk in July. 05/31/2020 - The RSM Team continued to assist the DOH Team with tasks and activities during May, which continued to help alleviate some of the bandwidth concerns for the DOH staff. Release 3.10 will be managed by RSM as a water-scrum-fall release, which should help limit the impact of minimal bandwidth for the DOH Solution Architect. IV&V will continue to monitor this issue in June. 04/30/2020 - The RSM Team continued to assist the DOH Team in tasks and activities during April, which helped to alleviate some of the bandwidth concerns for the DOH staff. However, like our March reporting period, with backlog grooming and release planning for future feature sets planned for upcoming releases, DOH staff bandwidth continues to be a concern. IV&V will continue to monitor this finding during the May reporting period. 03/31/2020 - The RSM Team assisted the DOH Team in tasks and activities during March, alleviating some of the bandwidth concerns for the DOH staff. However, with backlog grooming and release planning for future feature sets in releases 3.9 and 3.10, DOH staff bandwidth continues to be a concern. IV&V will continue to menitor the DOH staff. However, with backlog grooming and release planning for future feature sets in releases 3.9 and 3.10, DOH staff bandwidth continues to be a concern. IV&V will	Sprint Planning	Risk	Low	Open		D Macdonald
9.000	1/31/2020	The lack of a Product Roadmap that provides direction on the top product features to be delivered in the near term (next 3 months), midterm, and long term could have an adverse impact on the Project's scope and schedule.	BHA does not have a single, definitive Product Roadmap for Phase 3 that addresses the functionalities, features, and / or enhancements to be built in order to fully address BHA's business needs. IV&V met with RSM and BHA on this topic in January, and notes that the project is actively working to address this concern.	agile project on what functionalities/features are targeted to be built and released and when users can have access to these functionalities. Without a defined Roadmap the project may	Long Term Roadmap. IV&V recommends the Project complete this by the end of February 2020 to understand if there are any constraints	02/29/2020 - In February, the project further defined the Phase 3 Product Roadmap and aligned it with the Phase 3 Definition of Done. IV&V recommends the project continually review and update both the Product Roadmap and Definition of Done, adjusting as necessary. IV&V will continue to monitor the project's adherence to the Product Roadmap and progress against it but is closing out this concern as of the February report.	Project Management	Concern	N/A	Closed	Product Roadmap aligned with Definition of Done	V Ramesh

FINAL IVV Findings Log Jun 2020_V1

10.000		related "stay at home" order could hinder project activities and negatively impact the project schedule and budget.	at least until the end of April and some offices may be completely shut down until that time as well. Unclear if the order will extend beyond that date.	hindered, not only by required remote work by DOH and SI staff, but also by the flood of activities that could occur as the department could become overwhelmed processing and providing services due to the resulting economic impacts to citizens. Some stakeholders may be unable (due to stricter shutdown policies) or unwilling to perform these activities during this chaotic time. Planned SI on-site	setup, train, and assist stakeholders on remote work devices and tools and make every effort to help them to become highly functional with remote access technology (e.g. MS Teams/Skype). - IV&V recommends the project and DOH create a detailed, documented risk mitigation strategy and plan that is reviewed regularly and revised to address the current state of the COVID-19 threat and related impacts over the next 6 to 12 months. - IV&V recommends updates to the OCM Plan to include any new activities or updates to planned activities to aid the organization	06/30/2020 - The State's 'Safer at Home' orders ended on June 30th. IV&V notes that although staff are still remote, the project has continued to manage meeting monthly release schedules. As such, IV&V is reducing this risk to a Medium priority. 05/31/2020 - The COVID-19 pandemic continued to require more staff and management time than anticipated in May, as Departmental priorities are focused on providing services to clients. Both the DDD and CAMHD Product Owners have stated that a significant percentage of available managerial and staff time continues to be redirected to the Department's COVID-19 response, as opposed to being able to focus on the project. To date, project activities have not been impacted IV&V will continue to monitor this risk during the month of June. 04/30/2020 - During this reporting period, DOH's response to the COVID-19 pandemic required more staff time than anticipated, due to the time needed to plan for and provide services to its clients. Both the DDD and CAMHD Product Owners have stated that a significant percentage of available managerial and staff time has been redirected to the Department's COVID-19 response, as opposed to being able to focus on the project.	Project Management	Risk	Med	Open	Darren
11.000	5/31/2020	production.	There were a couple incidents during May where the code promoted to production did not fully meet all requirements of associated user stories for CAMHD Progress Notes. The components that were developed and implemented were functional, however the effort was complicated by additional requirements being added during development that necessitated additional changes to the design. IV&V will continue to monitor the design review activity for large user stories moving forward	If all requirements within a functional design are not met, users could experience the inability to complete required processes, resulting in incomplete data collection and potential issues in service delivery.		06/30/2020 - IV&V acknowledges the Project Team continued to spend additional time on the designs of complex user stories during June to ensure requirements and user story components were fully captured in design sessions. IV&V will continue to monitor in July.		Concern		In Progress	